Perioperative management of patients with concomitant liver diseases

Close metadata

Recommended articles:

Reconstruction of total portosystemic shunt into selective portosystemic shunt in a child. Pirogov Russian Journal of Surgery. 2023;(12):140-146

Preliminary findings of hepatocellular carcinoma screening in the at-risk population. Russian Journal of Evidence-Based Gastroenterology. 2023;(4):54-59

Trends in endovascular treatment and prevention of portal bleeding. Pirogov Russian Journal of Surgery. 2024;(3):38-44

Liver transplantation program at the Burnasyan Federal Biophysical Center: experience in 500 procedures. Pirogov Russian Journal of Surgery. 2024;(7):45-60

Liver cirrhosis prevalence among rural residents. Russian Journal of Preventive Medicine. 2024;(9):32-36

Safety profile of pressurized intraperitoneal aerosol chemotherapy in the treatment of ovarian cancer. P.A. Herzen Journal of Oncology. 2024;(5):25-30

Impact of alcohol consumption on nature of nutrition, metabolism and human target organs. Part 2. Basic principles of nutritional intervention. Russian Journal of Preventive Medicine. 2024;(10):131-136

Currently, both in developed and developing countries of the world, the incidence of liver and bile duct disease is steadily increasing, which makes the problem more urgent. The causes of the initial pathology of the liver, predisposing to the development of liver failure, are diverse — acute and chronic viral hepatitis, drug-induced hepatotoxic drugs, alcohol and drug use, other infectious and parasitic diseases, systemic and oncological diseases, etc. In clinical recommendations, features of preoperative examination and preparation of patients with concomitant liver diseases are presented. The influence of anesthetics on liver function and the effect of hepatic dysfunction on the pharmacokinetics of drugs are discussed. Complications arising in the postoperative period in patients with concomitant liver diseases (hepatic encephalopathy, ascites and spontaneous bacterial peritonitis, hepatorenal syndrome, bleeding from varicose veins of the esophagus, dilution hyponatremia) are considered according to the current recommendations of the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the European Society of Anaesthesiologists (ESA), the Russian Society of Surgeons, the Russian Society for the Study of the Liver.

Keywords:

diseases of the liver

acute liver failure

acute-on-chronic liver failure

cirrhosis

hepatic encephalopathy

ascites

hepatorenal syndrome

Authors:

Zabolotskikh I.B.

FGBOU VO «Kuban State Medical University» Ministry of Health of Russia, Krasnodar, Russia

SPIN RSCI: 5142-1661
Scopus AuthorID: 6508104506
ResearcherID: O-2705-2014
ORCID: 0000-0002-3623-2546

Gromova E.G.

N.N. Blokhin Cancer Research Center Russian Ministry of Health, Moscow, Russia

SPIN RSCI: 6518-2080
Scopus AuthorID: 57206253500
ORCID: 0000-0002-4633-8301

Lebedinskii K.M.

FGBOU VO «North-West State Medical University named after I.I. Mechnikov» Ministry of Health of Russia, St. Petersburg, Russia

SPIN RSCI: 3590-2308
Scopus AuthorID: 6602775085
ResearcherID: O-8655-2014
ORCID: 0000-0002-5752-4812

Lubnin A.Yu.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia, N.N. Burdenko Research Institute of Neurosurgery, Moscow, Russia, Department of Obstetrics and Gynecology, M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia

RSCI AuthorID: 370609
Scopus AuthorID: 57192157123
ORCID: 0000-0003-2595-5877

Osovskikh V.V.

N.N. Burdenko Russian National Applied Research Center of Neurosurgery, Moscow, Russia

SPIN RSCI: 7385-5940
Scopus AuthorID: 7801671940
ResearcherID: O-3344-2015
ORCID: 0000-0001-6121-4932

Sinkov S.V.

Kuban State Medical University, Krasnodar, Russia;
Regional Clinical Hospital №2, Krasnodar, Russia

SPIN RSCI: 4413-0869
Scopus AuthorID: 57218212478
ORCID: 0000-0003-4483-4077

Khoroshilov S.E.

A.M. Granova «RNTSRHT» of the Ministry of Health of Russia, St. Petersburg, Russia

SPIN RSCI: 7071-6642
Scopus AuthorID: 56737015600
ResearcherID: V-1770-2017
ORCID: 0000-0002-0427-8099

Schegolev A.V.

N.N. Burdenko Main Military Clinical Hospital, Moscow, Russia ,SM Kirov Military Medical Academy, St. Petersburg, Russia

SPIN RSCI: 4107-6860
Scopus AuthorID: 7003338841
ResearcherID: J-4326-2013
ORCID: 0000-0001-6431-439X

List of references:

EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failureq. European Association for the Study of the Liver. Journal of Hepatology. 2017;66:1047-1081.
Sviridova SP, Patyutko YuI, Somonova OV, Vlasenko OS, Sytov AV, Sotnikov AV. Rol' ishemii-reperfuzii pecheni v patogeneze poliorgannoj disfunktsii pri rasshirennykh khirurgicheskikh vmeshatel'stvakh v onkologii. Vestnik intensivnoj terapii. 2015;2:3-13.
Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541-553.
Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology. 2014;61:642-659.
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. European Association for the Study of the Liver. Journal of Hepatology. 2010;53:397-417.
Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-1026.
Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. Clin Chest Med. 2005;26:587-597.
Rai R, Nagral S, Nagraly A. Surgery in a Patient with Liver Disease. J Clin Exp Hepatol. 2012;2:238-246.
Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010;53:179-190.
Ruiz-del-Árbol L, Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol. 2015;21(41):11502-11521.
Zakhari S, Li TK. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology. 2007;46:2032-2039.
Gual A, Segura L, Contel M, Heather N, Colom J. AUDIT-3 and AUDIT-4: effectiveness of two short forms of the alcohol use disorders identification test. Alcohol Alcohol. 2002;37:591-596.
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. European Association for the Study of the Liver. Journal of Hepatology. 2012;57:399-420.
Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg. 2006;243:373-379.
Cucchetti A, Ercolani G, Vivarelli M, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl. 2006;12:966-971.
Jalan R, Pavesi M, Saliba F, Amoros A, Fernandez J, Holland-Fischer P, et al. The CLIF Consortium acute decompensation score (CLIF-C ADs) for prognosis of hospitalized cirrhotic patients without acute-on-chronic liver failure. J Hepatol. 2015;62:831-840.
Li N, Huang C, Yu K, Lu Q, Shi G, Zheng J. Validation of prognostic scores to predict short-term mortality in patients with HBV-related acute-on-chronic liver failure. The CLIF-C OF is superior to MELD, CLIF SOFA, and CLIF-C ACLF. Medicine. 2017;96(17):6802.
Stoelting RK, Dierdorf SF. Anesthesia and Co-existing Disease, 4rd ed. Elsevier Health Sciences. 2002;798.
Fabian JA. Anesthesia for Organ Transplantation. Philadelphia: GB Lippincott; 1992.
Zhilin IV. Prognozirovanie razvitiya razlichnyh form ostroj pechenochnoj nedostatochnosti u pacientov posle maloinvazivnogo drenirovaniya zhelchevyvodyashchih putej. Vestnik intensivnoj terapii. 2015;5:102-105.
Arroyo V, Moreau R, Jalan R, Ginès P. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. Journal of Hepatology. 2015;62:131-143.
Murray JM, Rowlands BJ, Trinick TR. Indocyanine green clearance and hepatic function during and after prolonged anaesthesia: Comparison of halothane with isoflurane. Br J Anaesth. 1992;68:168-171.
Gatacel C, Losser MR, Payen D. The postoperative effects of halothane versus isoflurane on hepatic artery and portal vein blood flow in humans. Anesth Analg. 2003;96:740-745.
Gelman S. General anesthesia and hepatic circulation. Can J Physiol Pharmacol. 1987;65:1762-1779.
Frink EJ, Morgan SE, Coetzee A, et al. The effects of sevoflurane, halothane, enflurane, and isoflurane on hepatic blood flow and oxygenation in chronically instrumented greyhound dogs. Anesthesiology. 1992;76:85-90.
Armbruster K, Noldge-Schomburg G, Dressler IMJ, et al: The effects of desflurane on splanchnic hemodynamics and oxygenation in the anesthetized pig. Anesth Analg. 1997;84:271-277.
Hartman JC, Pagel PS, Proctor LT, et al. Influence of desflurane, isoflurane and halothane on regional tissue perfusion in dogs. Can J Anaesth. 1992;39:877-887.
Aneman A, Pontén J, Fändriks L, et al. Splanchnic and renal sympathetic activity in relation to hemodynamics during isoflurane administration in pigs. Anesth Analg. 1995;80:135-142.
Saxena R, Zucker SD, Crawford JM. Anatomy and physiology of the liver. In: Zakim D, Boyer D, ed. Hepatology. A Textbook of Liver Disease, Philadelphia: WB Saunders; 2003.
Matsumoto N, Kotzumi M, Sugai M. Hepatolobectomy-induced depression of hepatic circulation and metabolism in the dog is counteracted by isoflurane, but not by halothane. Acta Anaesthesiol Scand. 1999;43:850-854.
Crawford MW, Lerman J, Saldivia V, et al. The effect of adenosine-induced hypotension on systemic and splanchnic hemodynamics during halothane or sevoflurane anesthesia in the rat. Anesthesiology. 1994;80:159-167.
Grundmann U, Zizzis A, Bauer C, Bauer M. In vivo effects of halothane, enflurane, and isoflurane on hepatic sinusoidal microcirculation. Acta Anaesthiol Scand. 1997;41:760-765.
Crawford MW, Lerman J, Saldivia V, et al. Hemodynamic and organ blood flow responses to halothane and sevoflurane anesthesia during spontaneous ventilation. Anesth Analg. 1992;75:1000-1006.
Conzen PF, Vollmar B, Habazettl H, et al. Systemic and regional hemodynamics of isoflurane and sevoflurane in rats. Anesth Analg. 1992;74:79-88.
Bito H, Ikeda K. Renal and hepatic function in surgical patients after low-flow sevoflurane or isoflurane anesthesia. Anesth Analg. 1996;82:173-176.
Ebert TJ, Messana LD, Uhrich TD, et al. Absence of renal and hepatic toxicity after four hours of 1.25 minimum alveolar anesthetic concentration sevoflurane anesthesia in volunteers. Anesth Analg. 1998;86:662-667.
Jones RM, Koblin DD, Cashman JN, et al. Biotransformation and hepato-renal function in volunteers after exposure to desflurane (I-653). Br J Anaesth. 1990;64:482-487.
Nishiyama T, Yokoyama T, Hanaoka K. Effects of sevoflurane and isoflurane anesthesia on arterial ketone body ratio and liver function. Acta Anaesthesiol Scand. 1999;43:347-351.
Obata R, Bito H, Ohmura M, et al. The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function. Anesth Analg. 2000;91:1262-1268.
Kim JW, Kim JD, Yu SB, Ryu SJ. Comparison of hepatic and renal function between inhalation anesthesia with sevoflurane and remifentanil and total intravenous anesthesia with propofol and remifentanil for thyroidectomy. Korean J Anesthesiol. 2013;64(2):112-116.
Rothenberg DM, Connor CJ, Tuman KJ. Anesteziya i gepatobiliarnaya sistema. V kn.: Anesteziya Ronal’da Millera. Pod red. R. Millera. Per. s angl. Pod obshch. red. K.M. Lebedinskogo. V 4 t. SPb.: CHelovek; 2015.].
Zaleski L, Abello D, Gold MI. Desflurane versus isoflurane in patients with chronic hepatic and renal disease. Anesth Analg. 1993;76:353-356.
Ko JS, Gwak MS, Choi SJ, Yang M, Kim MJ, Lee JY, Kim GS, Kwon CH, Joh JW. The effects of desflurane and sevoflurane on hepatic and renal functions after right hepatectomy in living donors. Transpl Int. 2010.
Debaene B, Goldfarb G, Braillon A, et al. Effects of ketamine, halothane, enflurane, and isoflurane on systemic and splanchnic hemodynamics in normovolemic and hypovolemic cirrhotic rats. Anesthesiology. 1990;73:118-124.
Soubhia AF, Lauz S, Montero EF, Menezes A, Mespaque LB, Facin E. Effects of the inhalational anesthetics halothane and sevoflurane on an experimental model of hepatic injury. Rev Bras Anestesiol. 2011;61(5):591-603, 324-330.
Thomson IA, Fitch W, Campbell D, et al.: Effects of ketamine on liver blood flow and hepatic oxygen consumption: Studies in the anaesthetized greyhound. Acta Anaesthesiol Scand. 1988;32:10-14.
González Gil A, Silván G, Illera JC. Effects of barbiturate administration on hepatic and renal biochemical parameters in new zealand white rabbits. Contemp Top Lab Anim Sci. 2005;44(6):43-45.
Yoshida H, Kudo T, Sawada M, Saito J, Tonosaki M, Hirota K. Effects of propofol and ketamine on postoperative hepatic and renal function: comparison between fentanyl and remifentanil as an adjuvant. Masui. 2012;61(8):794-799.
Kalkan Y, Tomak Y, Altuner D, Tumkaya L, Bostan H, Yilmaz A, Unal D, Kara A, Turan A. Hepatic effects of ketamine administration for 2 weeks in rats. Hum Exp Toxicol. 2013.
Ye L, Luo CZ, McCluskey SA, Pang QY, Zhu T. Propofol attenuates hepatic ischemia/reperfusion injury in an in vivo rabbit model. J Surg Res. 2012;178(2):65-70.
Kennedy JrWF, Everett GB, Cobb LA, et al. Simultaneous systemic and hepatic hemodynamic measurements during high spinal anesthesia in normal man. Anesth Analg. 1970;49:1016-1024.
Greitz T, Andreen M, Irestedt L. Haemodynamic and oxygen consumption in the dog during high epidural block with special reference to the splanchnic region. Acta Anaesthesiol Scand. 1983;27:211-217.
Tanaka N, Nagata N, Hamakawa T, Takasaki M. The effect of dopamine on hepatic blood flow in patients undergoing epidural anesthesia. Anesth Analg. 1997;85:286-290.
Darling JR, Murray JM, Hainsworth AM, et al. The effect of isoflurane or spinal anesthesia on indocyanine green disappearance rate in the elderly. Anesth Analg. 1994;78:706-709.
Vagts DA, Iber T, Puccini M, et al. The effects of thoracic epidural anesthesia on hepatic perfusion and oxygenation in healthy pigs during general anesthesia and surgical stress. Anesth Analg. 2003;97:1824-1832.
Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37:17-40.
Haberer JP, Schoeffler P, Couderc E, et al. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982;54:1267-1270.
Raucoules-Aimé M, Kaidomar M, Levron JC, et al. Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. Anesth Analg. 1997;84:1019-1024.
Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology. 1996;84:812-820.
Dumont L, Picard V, Marti RA, et al. Use of remifentanil in a patient with chronic hepatic failure. Br J Anaesth. 1998;81:265-267.
Pandele G, Chaux F, Salvadori C, et al. Thiopental pharmacokinetics in patients with cirrhosis. Anesthesiology. 1983;59:123-126.
Couderc E, Ferrier C, Harberer JP, et al. Thiopentone pharmacokinetics in patients with chronic alcoholism. Br J Anaesth. 1984;56:1393-1396.
Duvaldestin P, Chauvin M, Lebrault C, et al. Effect of upper abdominal surgery and cirrhosis upon the pharmacokinetics of methohexital. Acta Anaesthesiol Scand. 1991;35:159-163.
Servin F, Cockshott ID, Farinotti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth. 1990;65:177-183.
Trouvin JH, Farinotti R, Haberer JP, et al. Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. Br J Anaesth. 1988;60:762-767.
Baughman VL, Cunningham FE, Layden T. Pharmacokinetic/pharmacodynamic effects of dexmedetomidine in patients with hepatic failure. Anesth Analg. 2000;90(suppl):391.
Magorian T, Wood P, Caldwell J, et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg. 1995;80:754-759.
Cammu G, Bossuyt G, De Baerdemaeker L, et al. Dose requirements and recovery profile of an infusion of cisatracurium during liver transplantation. J Clin Anesth. 2002;14:135-139.
Fodale V, Santamaria LB. Laudanosine, an atracurium and cisatracurium metabolite. Eur J Anaesthesiol. 2002;19:466-473.
Head-Rapson AG, Devlin JC, Parker JC. Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth. 1994;73:613-618.
Thomas SD, Boyd AH. Prolonged neuromuscular block associated with acute fatty liver of pregnancy and reduced plasma cholinesterase. Eur J Anaesthesiol. 1994;11:245-249.
Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. Metab Brain Dis. 2004;19:281-312.
Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515-525.
Hassanein TI, Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci. 2008;53:529-538.
Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997;25:1351-1360.
Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046.
Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy. A metaanalysis. Dig Dis Sci. 1993;38:916-922.
Jiang Q, Xue-Hua J, Ming-Hua Z. L-ornithine-Laspartate in the management of hepatic encephalopathy: meta-analysis. J Gastroenterol Hepatol. 2009;24(1):9-14.
Rahimi RS, Singal AG, Cuthbert JA, Rockey DG. A randomized trial of polyethylene glycol 3350-electrolyte solution (PEG) and lactulose for patients hospitalized with acute hepatic encephalopathy. Hepatology. 2012;56:915-916, [abstr. 1546].
Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis. 2013;28:307-312.
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.
Sviridova SP, Patyutko YuI, Sotnikov AV. Sepsis i disfunktsiya pecheni — sovremennoe sostoyanie problemy. Vestnik intensivnoj terapii. 2016;1:3-12.
Runyon BA. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology. 2004;39:841-855.
Rimola A, Gracia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32:142-153.
Horon’ko YU.V., Martynov D.V., Kosovcev E.V., Lebedev YU.I. Perioperacionnoe soprovozhdenie portosistemnyh shuntiruyushchih vmeshatel’stv pri oslozhnennoj portal’noj gipertenzii u pacientov cirrozom pecheni. Vestnik intensivnoj terapii. 2017;1:67-72.
Sola-Vera J, Micana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37:1147-1153.
Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int. 2006;26:46-54.
Claria J, Kent JD, Lopez-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonaziotemic patients with cirrhosis and ascites. Hepatology. 2005;41:579-587.
Guevara M, Fernandez-Esparrach G, Alessandria C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology. 2004;40:646-651.
Rimola A, Salmeryn JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology. 1995;21:674-679.
Terg R, Cobas S, Fassio E, Landeira G, Rhos B, Vasen W, et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol. 2000;33:564-569.
Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther. 2006;23:75-84.
Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923-930.
Fabrizi F, Dixit V, Martin P. Metaanalysis: terlipressin therapy for hepatorenal syndrome. Aliment Pharmacol Ther. 2006;24:935-944.
Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized prospective double blind, placebo controlled study of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360-1368.
Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51:576-584.
Abid S, et al. Terlipressin vs Octreotide in bleeding esophageal varicel as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. The American Journal of Gastroenterology. 2009;104:21-29.
Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database of Systematic Reviews. 2003;1:CD002147.
Ahluwalia V, Wade JB, Thacker L, et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol. 2013;59:467-473.
Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver. 2002;22:2:20-25.
Hassanein TI, Tofteng F, Brown RS, et al. Randomized Controlled Study of Extracorporeal Albumin Dialysis for Hepatic Encephalopathy in Advanced Cirrhosis. Hepatology. 2007;46:1853-1862.
Saliba F, Camus C, Durand F, Mathurin P, Letierce A, Delafosse B, Barange K, Perrigault PF, Belnard M, Ichaï P, Samuel D. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med. 2013;159(8):522-531.
Banares R, Nevens F, Larsen FS, et al. Extracorporeal Albumin Dialysis With the Molecular Adsorbent Recirculating System in Acute-on-Chronic Liver Failure: The RELIEF Trial. Hepatology. 2013;57:1153-1162.
Gerth HU, Pohlen M, ThoÈlking G, PavenstaÈdt H, Brand M, Wilms C. et al. Molecular adsorbent recirculating system (MARS) in acute liver injury and graft dysfunction: Results from a case-control study. PLoS ONE. 2017;12(4):e0175529.
Gerth HU, Pohlen M, Brand M, et al. Molecular Adsorbent Recirculating System Can Reduce Short-Term Mortality Among Patients With Acute-on-Chronic Liver Failure — A Retrospective Analysis. Crit Care Med. 2017;45:1616-1624.
Zheng Z, Li X, Li Z, Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression. Experimental and therapeutic medicine. 2013;6:929-936.
Shen Yi, Wang Xu-Lin, Wang Bin, et al. Survival Benefits With Artificial Liver Support System for Acute-on-Chronic Liver Failure A Time Series-Based Meta-Analysis. Medicine. 2016;95(3):e2506.
Larsen FS, Schmidt LE, Wendon J, et al. Liver assisting with high-volume plasma exchange in patients with acute liver failure. Hepatol. 2010;52:376A.
Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, Triantafyllou E, Bernal W, Auzinger G, Shawcross D, Eefsen M, Bjerring P, Clemmesen JO, Hockerstedt K, Frederiksen HJ, Hansen B, Antoniades CG, Wendon J. High-volume plasma exchange in patients with acute liver failure: An open randomised controlledtrial. J Hepatol. 2016;64(1):69-78.
Lee JY, Kim SB, Chang JW, Park SK, Kwon SW, Song KW, Hwang S, Lee SG. Comparison of the molecular adsorbent recirculating system and plasmapheresis for patients with graft dysfunction after liver transplantation. Transplant Proc. 2010;42(7):2625-2530.
Yue-Meng Wan, Yu-Hua Li, Zhi-Yuan Xu, Jing Yang, Li-Hong Yang, Ying Xu, Jin-Hui Yang. Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir: A prospective study. Clin Apher. 2017;1-9.
Adani GL, Lorenzin D, Currò G, Sainz-Barriga M, Comuzzi C, Bresadola V, Avellini C, Baccarani U. Selective Bilirubin Removal by Plasma Treatment With Plasorba BR-350 for Early Cholestatic Graft Dysfunction. Transplantation Proceedings. 2007;39:1904-1906.
Fomin AM, Lobakov AI, Titova GV, Zakharov YuI. Otsenka ehffektivnosti plazmosorbtsii (Liver Support) pri pechenochnoj nedostatochnosti u bol'nykh s mekhanicheskoj zheltukhoj. Al'manakh klinicheskoj meditsiny. 2015;40:101-108..
Li M, Wang Z, Wang Y. Part of plasmapheresis with plasma filtration adsorptioncombined with continuous hemodiafiltration inthe treatment of severe acute liver failure. Experimental and therapeutic medicine. 2016;12:2582-2584.
Sokolov AA, Zakharov MV, Bel'skikh AN. Vozmozhnosti selektivnoj plazmofil'tratsii pri zabolevaniyakh pecheni. EHfferentnaya terapiya. 2013;9(1):103-104.].

Close metadata